Skip to content
Clinical Trials – home
Syndax Pharmaceuticals Inc.
Sponsor

Syndax Pharmaceuticals Inc.

United States 730 3rd Avenue Floor 9, 10017-3206, United States

About the sponsor

Clinical research in acute myeloid leukemia, including newly diagnosed AML with NPM1 mutation and relapsed or refractory acute leukemias, with attention to disease control, remission outcomes, and treatment response in genetically defined subgroups.

  • Acute Myeloid Leukemia
  • Relapsed/Refractory Leukemias
  • NPM1-mutated AML
  • KMT2A/MLL
  • NUP98

Interest extends to measurable residual disease clearance, complete remission, and event-free survival in combination with intensive chemotherapy.

About Specializations

Syndax Pharmaceuticals Inc. runs clinical trials in conditions such as Acute myeloid leukaemia, Acute leukaemia, Chronic graft versus host disease, Idiopathic pulmonary fibrosis, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

4 clinical trials

Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Syndax Pharmaceuticals Inc.
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Revumenib
  • Sponsor:Syndax Pharmaceuticals Inc.
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Axatilimab
  • Sponsor:Syndax Pharmaceuticals Inc.
Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Axatilimab
  • Sponsor:Syndax Pharmaceuticals Inc.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.